James OBrien - Humana Independent Director
| HUM Etf | USD 325.30 3.03 0.92% |
Mr. James J. OBrien is Independent Director of Humana Inc
| Age | 66 |
| Tenure | 18 years |
| Address | Humana Building, Louisville, KY, United States, 40202 |
| Phone | 502 580 1000 |
| Web | https://www.humana.com |
Humana Management Efficiency
The company has Return on Asset of 0.0634 % which means that on every $100 spent on assets, it made $0.0634 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1568 %, implying that it generated $0.1568 on every 100 dollars invested. Humana's management efficiency ratios could be used to measure how well Humana manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
| Showing other executives | One Year Return | ||
| James Rogers | Cigna Corp | 69 | |
| Eric Foss | Cigna Corp | 62 | |
| Timothy | Cigna Corp | N/A | |
| Aaref Hilaly | Guardant Health | 46 | |
| William Link | Edwards Lifesciences Corp | 73 | |
| Robert Williams | Laboratory of | 72 | |
| Ramona Sequeira | Edwards Lifesciences Corp | 55 | |
| Peter Neupert | Laboratory of | 65 | |
| Gunnar Hansen | Veeva Systems Class | N/A | |
| Eric Wiseman | Cigna Corp | 65 | |
| John Partridge | Cigna Corp | 71 | |
| Kerrii Anderson | Laboratory of | 63 | |
| Jane Henney | Cigna Corp | 69 | |
| Ronald Codd | Veeva Systems Class | 64 | |
| Roman Martinez | Cigna Corp | 71 | |
| Mark Carges | Veeva Systems Class | 57 | |
| George Kurian | Cigna Corp | 54 | |
| Richelle Parham | Laboratory of | 53 | |
| Paul LaViolette | Edwards Lifesciences Corp | 63 | |
| Paul Sekhri | Veeva Systems Class | 62 | |
| Timothy Cabral | Veeva Systems Class | 52 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0634 |
Humana Inc Money Managers
| David Jones, Independent Director | ||
| Kurt Hilzinger, Independent Chairman of the Board | ||
| Joseph Ventura, Chief Legal Officer and Corporate Secretary | ||
| David Nash, Independent Director | ||
| Vishal MD, Chief Officer | ||
| Susan Schick, Segment President Group and Military Business | ||
| Raquel Bono, Independent Director | ||
| Jorge Mesquita, Independent Director | ||
| Roy Beveridge, Senior Vice President Chief Medical Officer | ||
| W Dunbar, Independent Director | ||
| David Feinberg, Independent Director | ||
| Cynthia Zipperle, Senior Vice President, Chief Accounting Officer, Controller | ||
| Heather Carroll, Chief Digital Health and Analytics Officer | ||
| Marissa Peterson, Independent Director | ||
| Alan Wheatley, Segment President - Retail | ||
| James MBA, President COO | ||
| Kate Goodrich, Senior Officer | ||
| Timothy Wheatley, Segment Retail | ||
| Christopher Hunter, Segment President, Group and Military Business | ||
| Susan Diamond, Chief Financial Officer, Segment President, Home Business | ||
| Bruce Perkins, President - Health and Well-Being Services Segment | ||
| Andrew Agwunobi, President - Home Solutions Business | ||
| Steven McCulley, Chief Accounting Officer | ||
| Heather Cox, Chief Digital Health and Analytics Officer | ||
| Jessica Clark, Senior Improvement | ||
| James Brien, Independent Director | ||
| David Dintenfass, President Growth | ||
| Jennifer Bazante, Chief Marketing Officer | ||
| James OBrien, Independent Director | ||
| Amy Fry, Sr Communications | ||
| John III, Senior President | ||
| Christopher Todoroff, Senior Vice President General Counsel | ||
| Marcy Klevorn, Independent Director | ||
| Nwando Olayiwola, Senior Vice President Chief Health Equity Officer | ||
| William Mitchell, Independent Director | ||
| William Fleming, Segment President, Pharmacy Solutions and Chief Corporate Affairs Officer | ||
| Vishal Agrawal, Chief Strategy and Corporate Development Officer | ||
| Thomas Liston, President - Retail Segment | ||
| Brian Kane, Chief Financial Officer | ||
| Jody Bilney, Chief Consumer Officer and Sr. VP | ||
| Wayne Frederick, Independent Director | ||
| PharmD PharmD, Chief Solutions | ||
| Bethanie Stein, President Pharmacy | ||
| Betty Assapimonwait, President - Humana's South Florida Medicare | ||
| Frank DAmelio, Independent Director | ||
| Erin Champlin, Senior Experience | ||
| Timothy Huval, Chief Human Resource Officer, Chief Administrative Officer | ||
| Sue Schick, President - Military and Specialty Businesses | ||
| Elizabeth Bierbower, President - Employer Group Segment | ||
| T Wheatley, Segment President - Retail | ||
| Tracy Nolan, Senior MarketPoint | ||
| Christopher Kay, Chief Innovation Officer, Senior Vice President | ||
| Sam Deshpande, Chief Technology Officer, Chief Risk Officer | ||
| Bruce Broussard, CEO and President Director and Chairman of Executive Committee | ||
| George II, President Medicaid | ||
| Eric Tagliere, Senior CTO | ||
| Heidi Margulis, Senior Vice President - Public Affairs | ||
| Frank Bisignano, Independent Director | ||
| Karen DeSalvo, Independent Director | ||
| Samir Deshpande, Chief Information Officer | ||
| William Shrank, Chief Medical and Corporate Affairs Officer | ||
| Roy Dunbar, Independent Director | ||
| John Garratt, Independent Director | ||
| MD MBA, President CenterWell | ||
| Regina Nethery, Vice President - Investor Relations | ||
| Carolyn Tandy, Senior Vice President and Chief Inclusion and Diversity Officer | ||
| Jay Khosla, Senior Officer | ||
| William McDonald, Independent Director | ||
| JohnPaul Felter, Chief VP | ||
| Lisa Stoner, Vice Relations | ||
| Tim McClain, President - Government and Other Businesses | ||
| James Murray, COO and Executive VP | ||
| Brian LeClaire, Senior Vice President CIO | ||
| Michael Koeberlein, Senior Vice President Chief Accounting Officer, Controller | ||
| Karen Katz, Independent Director |
Humana Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Humana a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0634 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 30.95 B | ||||
| Shares Outstanding | 120.55 M | ||||
| Shares Owned By Insiders | 0.20 % | ||||
| Shares Owned By Institutions | 94.21 % | ||||
| Number Of Shares Shorted | 2.45 M | ||||
| Price To Earning | 19.12 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humana Inc. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
The market value of Humana Inc is measured differently than its book value, which is the value of Humana that is recorded on the company's balance sheet. Investors also form their own opinion of Humana's value that differs from its market value or its book value, called intrinsic value, which is Humana's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humana's market value can be influenced by many factors that don't directly affect Humana's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humana's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humana is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humana's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.